Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free GRCE Stock Alerts

Grace Therapeutics (GRCE) Financials

Grace Therapeutics logo
$2.40 -0.01 (-0.21%)
As of 10:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Grace Therapeutics

Annual Income Statements for Grace Therapeutics

This table shows Grace Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 2/29/2016 2/28/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.71 -8.05 -17 -39 -26 -20 -9.82 -42 -13 -9.57 -7.79
Consolidated Net Income / (Loss)		 -4.71 -7.86 -17 -39 -26 -20 -9.82 -42 -13 -9.57 -7.79
Net Income / (Loss) Continuing Operations		 -4.71 -8.05 -17 -39 -26 -20 -9.82 -42 -13 -9.57 -7.79
Total Pre-Tax Income 		-4.71 -7.96 -17 -39 -26 -20 -10 -52 -15 -13 -9.49
Total Operating Income		 -7.17 -7.87 -15 -34 -24 -16 -16 -52 -13 -17 -11
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.20 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.08 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 7.17 7.87 15 34 24 17 16 52 13 17 11
Selling, General & Admin Expense		 1.53 2.45 3.12 4.54 5.80 5.52 9.26 7.61 6.68 7.17 8.67
Research & Development Expense		 5.64 5.42 12 29 16 4.17 5.56 9.97 4.68 9.51 2.41
Total Other Income / (Expense), net		 2.46 -0.09 -1.40 -4.96 -1.08 -3.26 5.12 0.18 -1.83 3.91 1.58
Interest & Investment Income		 - - - - - - - 0.25 0.91 0.71 0.69
Other Income / (Expense), net		 2.46 -0.09 -1.40 -4.96 -1.08 -3.26 5.12 -0.06 -2.74 3.20 0.90
Income Tax Expense		 0.00 0.10 0.00 - - 0.00 -0.65 -9.54 -1.83 -3.20 -1.70
Basic Earnings per Share		 ($0.59) ($0.97) ($1.23) ($0.73) ($0.30) ($1.33) ($0.27) ($5.71) ($1.35) ($0.79) ($0.47)
Weighted Average Basic Shares Outstanding		 10.66M 10.79M 17.49M 54.29M 84.58M 14.83M 36.84M 7.44M 9.53M 12.09M 16.51M
Diluted Earnings per Share		 ($0.59) ($0.97) ($1.23) ($0.73) ($0.30) ($1.33) ($0.27) ($5.71) ($1.35) ($0.79) ($0.47)
Weighted Average Diluted Shares Outstanding		 10.66M 10.79M 17.49M 54.29M 84.58M 14.83M 36.84M 7.44M 9.53M 12.09M 16.51M
Weighted Average Basic & Diluted Shares Outstanding		 10.66M 10.79M 17.49M 54.29M 84.58M 14.83M 36.84M 44.61M 9.40M - 16.27M

Quarterly Income Statements for Grace Therapeutics

This table shows Grace Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 6/30/2024 9/30/2023 12/31/2023 3/31/2024 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.62 -3.27 -2.39 -4.57 -3.43 -4.16 -3.36 -0.94 -2.32 -1.18
Consolidated Net Income / (Loss)		 -2.62 -3.27 -2.39 -4.57 -3.43 -4.16 -3.36 -0.94 -2.32 -1.18
Net Income / (Loss) Continuing Operations		 -2.62 -3.27 -2.39 -4.57 -3.43 -4.16 -3.36 -0.94 -2.32 -1.18
Total Pre-Tax Income 		-3.34 -3.72 -2.60 -5.03 -4.28 -4.76 -3.36 -0.94 -2.32 -2.88
Total Operating Income		 -4.96 -2.09 -3.04 -2.75 -4.83 -3.70 -3.09 -2.53 -2.45 -3.01
Total Operating Expenses		 4.96 2.09 3.04 2.75 4.83 3.70 3.09 2.53 2.45 3.01
Selling, General & Admin Expense		 2.26 1.63 1.60 1.20 1.86 1.51 2.14 1.96 1.99 2.59
Research & Development Expense		 2.71 0.46 1.44 0.07 2.98 2.19 0.96 0.57 0.46 0.42
Total Other Income / (Expense), net		 1.62 -1.63 0.44 -2.27 0.55 -1.06 -0.27 1.59 0.13 0.13
Interest & Investment Income		 0.24 0.21 0.32 0.15 0.17 0.14 0.21 0.17 0.17 0.14
Other Income / (Expense), net		 1.39 -1.84 0.13 -2.42 0.38 -1.19 -0.48 1.42 -0.04 -0.01
Income Tax Expense		 -0.72 -0.45 -0.21 -0.45 -0.85 -0.61 0.00 0.00 0.00 -1.70
Basic Earnings per Share		 ($0.24) ($0.43) ($0.21) ($0.48) ($0.30) ($0.36) ($0.21) ($0.06) ($0.14) ($0.06)
Weighted Average Basic Shares Outstanding		 10.93M 7.55M 11.51M 9.53M 11.51M 11.51M 15.92M 15.92M 16.93M 16.51M
Diluted Earnings per Share		 ($0.24) ($0.43) ($0.21) ($0.48) ($0.30) ($0.36) ($0.21) ($0.06) ($0.14) ($0.06)
Weighted Average Diluted Shares Outstanding		 10.93M 7.55M 11.51M 9.53M 11.51M 11.51M 15.92M 15.92M 16.93M 16.51M
Weighted Average Basic & Diluted Shares Outstanding		 10.14M 9.40M 9.40M 9.40M 10.14M 10.14M 13.83M 14.13M 15.47M 16.27M

Annual Cash Flow Statements for Grace Therapeutics

This table details how cash moves in and out of Grace Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 2/29/2016 2/28/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 1.28 5.66 -1.20 11 -2.63 37 -21 -2.46 -4.87 -0.87 -5.16
Net Cash From Operating Activities		 -4.90 -4.66 -9.71 -24 23 -14 -17 -16 -12 -15 -8.87
Net Cash From Continuing Operating Activities		 -4.90 -4.66 -9.71 -24 -23 -14 -17 -16 -12 -15 -8.87
Net Income / (Loss) Continuing Operations		 -4.71 -7.86 -17 -39 -26 -20 -9.82 -42 -13 -9.57 -7.79
Consolidated Net Income / (Loss)		 -4.71 -7.86 -17 -39 26 -20 -9.82 -42 -13 -9.57 -7.79
Depreciation Expense		 0.04 0.14 0.27 0.38 -0.41 0.14 0.00 0.12 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 -1.95 0.57 2.12 6.14 -0.47 4.44 -4.63 26 1.77 -5.69 -1.80
Changes in Operating Assets and Liabilities, net		 -0.03 0.74 2.78 6.08 0.23 - -2.79 0.18 -1.26 0.34 0.72
Net Cash From Investing Activities		 6.14 5.18 -0.32 -9.12 8.14 -9.86 -3.52 13 0.10 0.00 0.00
Net Cash From Continuing Investing Activities		 6.14 5.18 -0.32 -9.12 8.14 -9.86 -3.52 13 0.10 0.00 0.00
Purchase of Investments		 -8.98 -9.58 -0.02 -8.88 -1.92 -9.81 -35 -5.02 -6.55 -0.02 0.00
Sale and/or Maturity of Investments		 15 17 0.00 0.00 10 0.02 31 18 6.57 0.02 0.00
Net Cash From Financing Activities		 -0.00 5.18 8.84 44 13 59 0.00 0.30 7.36 14 3.71
Net Cash From Continuing Financing Activities		 -0.00 5.18 8.84 44 13 59 0.00 0.30 7.36 14 3.71
Repurchase of Common Equity		 -0.00 0.00 0.00 0.00 - - - - -0.16 -0.97 -0.33
Issuance of Common Equity		 - - - - 6.98 59 0.00 0.30 7.50 15 0.00
Other Financing Activities, net		 -0.00 -0.01 -0.00 -0.03 7.75 0.16 - - 0.02 0.00 4.04

Quarterly Cash Flow Statements for Grace Therapeutics

This table details how cash moves in and out of Grace Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 6/30/2024 9/30/2023 12/31/2023 3/31/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -3.61 2.73 -8.45 4.46 -4.10 11 -2.13 -3.14 1.81 -1.70
Net Cash From Operating Activities		 -3.60 -4.76 -1.89 -2.09 -4.12 -2.95 -1.80 -3.14 -2.23 -1.70
Net Cash From Continuing Operating Activities		 -3.60 -4.76 -1.87 -2.09 -4.12 -2.95 -1.80 -3.14 -2.23 -1.70
Net Income / (Loss) Continuing Operations		 -2.62 -4.68 -2.39 -3.17 -4.16 0.64 -3.36 -0.94 -2.31 -1.18
Consolidated Net Income / (Loss)		 -2.62 -4.68 -2.39 -3.17 -4.16 0.64 -3.36 -0.94 -2.31 -1.18
Depreciation Expense		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 -1.16 4.02 0.22 -0.57 1.34 -5.71 0.79 -1.22 0.15 -1.52
Changes in Operating Assets and Liabilities, net		 0.18 -4.10 0.30 1.65 -1.30 2.12 0.77 -0.98 -0.07 1.00

Annual Balance Sheets for Grace Therapeutics

This table presents Grace Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets		 19 18 37 23 62 129 79 73 72 67
Total Current Assets		 7.72 7.36 28 18 62 45 29 24 23 17
Cash & Equivalents		 7.34 6.37 17 14 51 30 28 23 22 17
Note & Lease Receivable		 - - - - - - - 0.72 0.13 0.02
Prepaid Expenses		 0.23 0.31 0.84 0.98 0.34 0.72 0.60 0.28 0.45 0.38
Plant, Property, & Equipment, net		 0.00 2.19 2.11 0.00 0.00 0.25 0.10 0.02 0.02 0.01
Plant, Property & Equipment, gross		 - - - - - 0.25 0.10 0.02 0.02 0.01
Total Noncurrent Assets		 11 8.25 6.82 4.39 0.09 83 50 49 49 49
Goodwill		 - - - - - 13 8.14 8.14 8.14 8.14
Intangible Assets		 9.30 7.80 6.39 4.24 0.00 70 41 41 41 41
Total Liabilities & Shareholders' Equity		 19 18 37 23 62 129 79 73 72 67
Total Liabilities		 2.82 11 26 9.86 6.80 20 11 12 5.38 2.76
Total Current Liabilities		 1.60 5.19 14 7.40 1.58 3.26 3.41 1.68 1.93 2.15
Accounts Payable		 1.60 5.19 12 7.32 1.49 3.16 3.34 1.68 1.93 2.15
Total Noncurrent Liabilities		 1.21 1.25 12 2.46 5.22 17 7.76 9.87 3.45 0.61
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - 17 7.35 5.51 2.31 0.61
Other Noncurrent Operating Liabilities		 1.21 - 12 2.46 5.22 0.20 0.41 4.36 1.14 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 16 6.38 11 13 56 108 68 62 67 64
Total Preferred & Common Equity		 16 6.38 11 13 56 108 68 62 67 64
Preferred Stock		 - - - - - - - 0.00 0.00 0.00
Total Common Equity		 16 6.38 11 13 56 108 68 62 67 64
Common Stock		 54 62 119 147 208 270 272 279 293 298
Retained Earnings		 -38 -56 -101 -126 -146 -156 -198 -211 -221 -228
Accumulated Other Comprehensive Income / (Loss)		 - - -7.14 -7.89 -6.33 -6.04 -6.04 -6.04 -6.04 -6.04

Quarterly Balance Sheets for Grace Therapeutics

This table presents Grace Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2024 9/30/2023 12/31/2023 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025
Total Assets		 70 78 76 65 61 70 67 68
Total Current Assets		 20 29 27 16 12 21 17 19
Cash & Equivalents		 19 27 19 15 11 20 17 19
Note & Lease Receivable		 - - - 0.42 0.30 0.02 0.02 0.02
Prepaid Expenses		 0.62 1.04 0.81 0.48 0.58 0.50 0.42 0.52
Plant, Property, & Equipment, net		 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.01
Plant, Property & Equipment, gross		 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.01
Total Noncurrent Assets		 49 49 49 49 49 49 49 49
Goodwill		 8.14 8.14 8.14 8.14 8.14 8.14 8.14 8.14
Intangible Assets		 41 41 41 41 41 41 41 41
Total Liabilities & Shareholders' Equity		 70 78 76 65 61 70 67 68
Total Liabilities		 10 11 12 9.22 9.09 6.26 3.76 3.60
Total Current Liabilities		 2.60 1.40 1.77 2.67 1.97 2.32 1.25 1.28
Accounts Payable		 2.60 1.35 1.75 2.67 1.97 2.32 1.25 1.28
Total Noncurrent Liabilities		 7.75 10 9.74 6.54 7.11 3.94 2.51 2.31
Noncurrent Deferred & Payable Income Tax Liabilities		 4.79 6.61 6.40 3.94 3.33 2.31 2.31 2.31
Other Noncurrent Operating Liabilities		 2.96 3.46 3.33 2.60 3.78 1.63 0.20 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 59 67 65 56 52 64 63 65
Total Preferred & Common Equity		 59 67 65 56 52 64 63 65
Preferred Stock		 - - - - 0.00 0.00 0.00 0.00
Total Common Equity		 59 67 65 56 52 64 63 65
Common Stock		 279 278 279 279 280 294 294 298
Retained Earnings		 -214 -206 -208 -217 -221 -224 -225 -227
Accumulated Other Comprehensive Income / (Loss)		 -6.04 -6.04 -6.04 -6.04 -6.04 -6.04 -6.04 -6.04

Annual Metrics And Ratios for Grace Therapeutics

This table displays calculated financial ratios and metrics derived from Grace Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 2/29/2016 2/28/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 25,638,215.00 78,132,734.00 78,132,734.00 179,495,705.00 44,288,183.00 44,612,831.00 9,399,404.00 10,139,861.00 10,139,861.00
DEI Adjusted Shares Outstanding		 0.00 0.00 534,129.00 1,627,765.00 1,627,765.00 3,739,494.00 7,381,364.00 7,435,472.00 9,399,404.00 10,139,861.00 10,139,861.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -31.21 -24.18 -15.67 -5.26 -1.33 -5.71 -1.37 -0.94 -0.77
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -107.65% -140.39% -155.09% 25.26% 32.62% 44.19% -397.69% 70.08% 13.56% 24.50%
EBIT Growth		 0.00% -68.93% -109.49% -136.14% 35.19% 22.87% 46.81% -398.87% 70.13% 13.58% 24.48%
NOPAT Growth		 0.00% -9.82% -93.98% -125.33% 28.97% 32.81% 5.06% -234.56% 75.36% -29.78% 33.59%
Net Income Growth		 0.00% -66.88% -112.07% -136.14% 35.19% 22.87% 50.10% -332.11% 69.71% 25.56% 18.55%
EPS Growth		 0.00% -64.41% -26.80% 40.65% 58.90% -343.33% 79.70% -332.11% 76.36% 41.48% 40.51%
Operating Cash Flow Growth		 0.00% 4.93% -108.24% -151.45% 194.05% -162.39% -20.36% 7.67% 22.50% -20.85% 40.49%
Free Cash Flow Firm Growth		 0.00% 0.00% 79.52% -220.01% -181.15% 64.44% -754.67% 84.80% 37.73% -127.06% 41.45%
Invested Capital Growth		 0.00% 0.00% -86.26% -1,186.96% 71.41% -52.69% 1,200.48% -37.65% -3.31% 14.81% 5.49%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -393.95% 61.96% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -401.86% 62.32% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 39.83% 19.29% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -401.86% 64.18% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -1,230.00% 80.58% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -28.00% -34.46% 0.00% 0.00% -6.17% 12.43%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -460.56% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -109.10% -1.31% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 61.22% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -9,568.37% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -8,377.04% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -10,039.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -10,039.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 98.78% 100.00% 100.00% 100.00% 100.00% 93.81% 81.64% 87.52% 74.94% 82.09%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.53% 94.16% 94.72% 93.27%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -48.25% -147.09% -451.95% -212.26% -57.33% -11.98% -48.15% -19.82% -14.91% -11.94%
Cash Return on Invested Capital (CROIC)		 0.00% -323.05% -58.17% 0.00% 0.00% 0.00% -126.07% -23.61% -19.46% -41.85% -22.31%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -46.13% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -46.13% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -48.25% -147.09% -451.95% -212.26% -57.33% -11.98% -48.15% -19.82% -14.91% -11.94%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -48.25% -261.48% -356.41% -196.34% -35.35% -9.07% -62.44% -20.82% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.02 -5.51 -11 -24 -17 -11 -11 -37 -9.00 -12 -7.75
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -5,863.93% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -64.10% -95.87% -103.38% -40.77% -20.90% 2.07% -16.47% -15.16% 9.34% -0.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -194.13% - - - - -14.57% -17.53% -12.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 38.78% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 2,816.84% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 2,129.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 8,438.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.71 -7.96 -17 -39 -26 -20 -10 -52 -16 -13 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.92 -6.07 -15 -37 -28 -19 -10 -52 -16 -13 -10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 2.37 0.00 0.00 0.00 0.30 0.52 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 5.61 0.00 0.00 0.00 1.10 2.58 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.20 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.45 -0.55 -1.70 -1.72 -1.14 -0.64 -0.41 -0.39 -0.35 -0.30
Leverage Ratio		 0.00 1.17 1.63 3.14 2.49 1.24 1.17 1.18 1.18 1.13 1.06
Compound Leverage Factor		 0.00 1.17 1.63 3.14 2.49 1.24 1.17 1.17 1.11 1.07 0.99
Debt to Total Capital		 0.00% 0.00% 16.39% 10.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 10.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 16.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 83.61% 89.03% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 -0.09 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.35 0.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.12 -0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.48 1.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -6.27 0.00 0.00 0.00 -4.19 -2.70 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 4.81 1.42 2.05 2.50 39.50 13.89 8.59 14.26 11.77 8.10
Quick Ratio		 0.00 4.67 1.34 1.97 2.00 38.80 13.56 8.41 14.09 11.53 7.92
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -14 -2.96 -9.48 -27 -9.48 -81 -12 -7.67 -17 -10
Operating Cash Flow to CapEx		 -2,381.88% -248.18% -2,751.43% -4,639.43% 7,194.67% -20,752.17% 0.00% -93,605.88% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.36 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 1,001.89 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 21,160.39 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -20,158.51 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 8.96 1.23 -13 -3.82 -5.84 64 40 39 44 47
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -0.04 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 8.96 -7.73 -15 9.55 -2.02 70 -24 -1.33 5.74 2.44
Enterprise Value (EV)		 0.00 0.00 0.00 1.73 0.00 0.00 0.00 -7.37 9.19 0.00 0.00
Market Capitalization		 0.00 0.00 0.00 26 0.00 0.00 0.00 21 32 0.00 0.00
Book Value per Share		 $0.00 $1.51 $0.36 $0.43 $0.17 $0.31 $2.44 $1.52 $6.57 $5.51 $3.87
Tangible Book Value per Share		 $0.00 $0.65 ($0.08) $0.18 $0.11 $0.31 $0.58 $0.42 $1.33 $1.43 $0.89
Total Capital		 0.00 16 7.63 12 13 56 108 68 62 67 64
Total Debt		 0.00 0.00 1.25 1.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 1.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -7.34 -5.15 -24 -14 -61 -44 -28 -23 -22 -17
Capital Expenditures (CapEx)		 0.21 1.88 0.35 0.53 0.32 0.07 0.00 0.02 -0.09 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.22 -4.21 -10 -3.17 0.06 -1.64 -2.01 -0.68 -1.35 -1.74
Debt-free Net Working Capital (DFNWC)		 0.00 6.11 2.17 16 11 61 42 26 22 21 15
Net Working Capital (NWC)		 0.00 6.11 2.17 14 11 61 42 26 22 21 15
Net Nonoperating Expense (NNE)		 -0.31 2.35 5.98 15 8.41 8.18 -1.09 5.92 3.86 -2.11 0.04
Net Nonoperating Obligations (NNO)		 0.00 -7.34 -5.15 -24 -17 -61 -44 -28 -23 -22 -17
Total Depreciation and Amortization (D&A)		 1.79 1.88 2.07 2.12 -2.32 0.92 0.00 0.12 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 31.63% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 31,016.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 31,016.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($45.60) $0.00 ($0.17) ($0.27) ($5.70) ($1.35) ($0.79) ($0.47)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 25.64M 1.63M 92.49M 208.38M 44.44M 7.44M 9.53M 12.09M 16.51M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($45.60) $0.00 ($0.17) ($0.27) ($5.70) ($1.35) ($0.79) ($0.47)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 25.64M 1.63M 92.49M 208.38M 44.44M 7.44M 9.53M 12.09M 16.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($45.60) $0.00 ($0.17) ($0.27) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 17.49M 1.13M 92.49M 118.63M 36.84M 7.44M 9.40M 0.00 16.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.02 -5.51 -11 -24 -17 -7.50 -11 -13 -7.96 -12 -7.75
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -3,827.14% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -10,039.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.02% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% -1.26% -10.11% -4.20%

Quarterly Metrics And Ratios for Grace Therapeutics

This table displays calculated financial ratios and metrics derived from Grace Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 6/30/2024 9/30/2023 12/31/2023 3/31/2024 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 9,399,404.00 7,448,033.00 9,399,404.00 9,399,404.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00
DEI Adjusted Shares Outstanding		 9,399,404.00 7,448,033.00 9,399,404.00 9,399,404.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.28 -0.44 -0.25 -0.49 -0.34 -0.41 -0.33 -0.09 -0.23 -0.12
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 19.46% 0.00% 0.00% 0.00% -13.59% -68.02% 0.00% 75.09% 49.31% 0.00%
EBIT Growth		 19.57% 0.00% 0.00% 0.00% -13.36% -68.03% 0.00% 75.09% 49.27% 0.00%
NOPAT Growth		 -11.43% 0.00% 0.00% 0.00% -130.93% -21.72% 0.00% 47.65% 33.88% 0.00%
Net Income Growth		 34.95% 0.00% 0.00% 0.00% -4.86% -73.78% 0.00% 72.67% 44.28% 0.00%
EPS Growth		 55.56% 0.00% 0.00% 0.00% 30.23% -71.43% 0.00% 80.00% 61.11% 0.00%
Operating Cash Flow Growth		 42.37% 0.00% 0.00% 0.00% 0.00% -117.49% 0.00% 0.00% 45.81% 42.62%
Free Cash Flow Firm Growth		 -105.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -46.79% -66.64% 0.00%
Invested Capital Growth		 -5.68% 0.00% 0.00% 0.00% 3.08% 3.84% 0.00% 12.19% 12.50% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -9.73% 25.72% -77.52% 0.00% -9.87% 0.00% 68.86% -123.60% -21.43%
EBIT Q/Q Growth		 0.00% -9.93% 25.85% -77.50% 0.00% -9.92% 0.00% 68.88% -123.87% -21.37%
NOPAT Q/Q Growth		 0.00% 57.85% -45.46% 9.50% 0.00% 23.33% 0.00% 18.16% 3.16% -22.87%
Net Income Q/Q Growth		 0.00% -25.07% 26.95% -91.22% 0.00% -21.07% 0.00% 72.10% -146.80% 49.11%
EPS Q/Q Growth		 0.00% -79.17% 51.16% -128.57% 0.00% -20.00% 0.00% 71.43% -133.33% 57.14%
Operating Cash Flow Q/Q Growth		 0.00% -32.29% 60.23% -10.36% 0.00% 0.00% 39.03% -74.51% 29.05% 23.99%
Free Cash Flow Firm Q/Q Growth		 0.00% 100.00% 0.00% 0.00% 0.00% 10.76% 0.00% 0.00% -1.30% 100.00%
Invested Capital Q/Q Growth		 0.00% -0.54% -0.44% -2.09% 0.00% 0.29% 0.00% 5.54% 0.57% 1.51%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 78.33% 88.01% 92.00% 90.97% 80.11% 87.29% 100.00% 100.00% 100.00% 40.93%
Interest Burden Percent		 93.43% 94.61% 89.16% 97.14% 96.14% 97.18% 94.25% 84.50% 93.16% 95.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -66.50% 0.00% 0.00% -19.82% 0.00% 0.00% 0.00% 0.00% 0.00% -11.94%
Cash Return on Invested Capital (CROIC)		 -83.72% 0.00% 0.00% -19.80% 0.00% 0.00% 0.00% 0.00% 0.00% -21.73%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -66.50% 0.00% 0.00% -19.82% 0.00% 0.00% 0.00% 0.00% 0.00% -11.94%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.47 -1.46 -2.13 -1.93 -3.38 -2.59 -2.16 -1.77 -1.71 -2.11
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 4.18% -6.70% -1.04% -11.49% -0.24% -8.64% -5.99% 5.20% -4.04% 5.47%
Return On Investment Capital (ROIC_SIMPLE)		 -5.85% - -3.29% -3.12% -6.02% -4.97% -3.40% -2.82% -2.64% -3.30%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.58 -3.93 -2.92 -5.17 -4.46 -4.90 -3.57 -1.11 -2.49 -3.02
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.58 -3.92 -2.91 -5.17 -4.46 -4.90 -3.57 -1.11 -2.48 -3.01
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.46 0.00 0.42 0.52 0.54 0.73 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 2.72 0.00 1.76 2.58 4.43 13.20 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.20 0.00 0.05 0.24 0.37 0.65 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.33 -0.40 -0.39 -0.37 -0.34 -0.31 -0.31 -0.27 -0.25 -0.27
Leverage Ratio		 1.16 1.17 1.18 1.18 1.17 1.18 1.10 1.11 1.11 1.06
Compound Leverage Factor		 1.08 1.11 1.05 1.14 1.12 1.14 1.04 0.94 1.03 1.01
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.56 0.00 0.00 -2.23 0.00 0.00 0.00 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 7.86 20.68 15.19 14.26 6.01 6.06 8.87 13.89 14.96 8.10
Quick Ratio		 7.62 19.93 14.73 14.09 5.83 5.76 8.65 13.56 14.56 7.92
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.07 0.00 0.00 0.00 -4.61 -4.11 0.00 -6.76 -6.85 0.00
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 40 40 40 39 41 41 44 46 46 47
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.41 0.00 0.00 0.00 1.23 1.52 0.00 4.99 5.14 0.00
Enterprise Value (EV)		 8.04 0.00 2.05 9.19 15 27 0.00 0.00 0.00 0.00
Market Capitalization		 27 0.00 27 32 30 38 0.00 0.00 0.00 0.00
Book Value per Share		 $6.32 $8.96 $6.88 $6.57 $5.54 $5.14 $3.99 $3.94 $3.83 $3.87
Tangible Book Value per Share		 $1.07 $2.35 $1.64 $1.33 $0.68 $0.28 $0.90 $0.85 $0.92 $0.89
Total Capital		 59 67 65 62 56 52 64 63 65 64
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -19 -27 -25 -23 -15 -11 -20 -17 -19 -17
Capital Expenditures (CapEx)		 0.00 0.00 0.00 -0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.58 0.48 0.00 -0.68 -1.78 -1.09 -1.80 -0.81 -0.75 -1.74
Debt-free Net Working Capital (DFNWC)		 18 27 25 22 13 9.97 18 16 18 15
Net Working Capital (NWC)		 18 27 25 22 13 9.97 18 16 18 15
Net Nonoperating Expense (NNE)		 -0.86 1.81 0.26 2.64 0.05 1.56 1.20 -0.83 0.60 -0.93
Net Nonoperating Obligations (NNO)		 -19 -27 -25 -23 -15 -11 -20 -17 -19 -17
Total Depreciation and Amortization (D&A)		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.24) ($0.43) ($0.21) ($0.48) ($0.30) ($0.36) ($0.21) ($0.06) ($0.14) ($0.06)
Adjusted Weighted Average Basic Shares Outstanding		 10.93M 7.55M 11.51M 9.53M 11.51M 11.51M 15.92M 15.92M 16.93M 16.51M
Adjusted Diluted Earnings per Share		 ($0.24) ($0.43) ($0.21) ($0.48) ($0.30) ($0.36) ($0.21) ($0.06) ($0.14) ($0.06)
Adjusted Weighted Average Diluted Shares Outstanding		 10.93M 7.55M 11.51M 9.53M 11.51M 11.51M 15.92M 15.92M 16.93M 16.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.48) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 10.14M 9.40M 9.40M 9.40M 10.14M 0.00 0.00 0.00 0.00 16.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.47 -1.46 -2.13 -0.89 -3.38 -2.59 -2.16 -1.77 -1.71 -2.11
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -1.26% 0.00% 0.00% 0.00% 0.00% 0.00% -4.20%

Financials Breakdown Chart

Grace Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Grace Therapeutics' fiscal year ends in March. Their fiscal year 2026 ended on March 31, 2026.

In the past 10 years, Grace Therapeutics' net income has ranged from -$42.43 million in 2023 to -$4.71 million in 2016, and is currently -$7.79 million as of their latest financial filing in 2026. See where experts think Grace Therapeutics is headed by visiting Grace Therapeutics' forecast page.

Grace Therapeutics' total operating income in 2026 was -$11.08 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.08 million

Over the last 10 years, Grace Therapeutics' total revenue changed from $0.00 in 2016 to $0.00 in 2026, a change of 0.0%.

Grace Therapeutics' total liabilities were at $2.76 million at the end of 2026, a 48.8% decrease from 2025, and a 2.1% decrease since 2017.

In the past 9 years, Grace Therapeutics' cash and equivalents has ranged from $6.37 million in 2018 to $50.94 million in 2021, and is currently $16.98 million as of their latest financial filing in 2026.

Over the last 10 years, Grace Therapeutics' book value per share changed from 0.00 in 2016 to 3.87 in 2026, a change of 387.0%.


Related Companies

Financial statements for NASDAQ:GRCE last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel